Literature DB >> 27813466

Flow diversion in the treatment of aneurysms: a randomized care trial and registry.

Jean Raymond1, Jean-Christophe Gentric1,2, Tim E Darsaut3, Daniela Iancu4, Miguel Chagnon5, Alain Weill1, Daniel Roy1.   

Abstract

OBJECTIVE The Flow Diversion in the Treatment of Intracranial Aneurysm Trial (FIAT) was designed to guide the clinical use of flow diversion, an innovative method to treat intracranial aneurysms, within a care trial and to study safety and efficacy. METHODS FIAT, conducted in 3 Canadian hospitals, proposed randomized allocation to flow diversion or standard management options (observation, coil embolization, parent vessel occlusion, or clip placement), and a registry of non-randomized patients treated with flow diversion. The primary safety outcome was death or dependency (modified Rankin Scale score > 2) at 3 months, to be determined for all patients who received flow diversion at any time. The primary efficacy outcome was angiographic occlusion at 3-12 months combined with an independent clinical outcome. RESULTS Of 112 participating patients recruited between May 2, 2011, and February 25, 2015, 78 were randomized (39 in each arm), and 34 received flow diversion within the registry. The study was halted due to safety concerns. Twelve (16%) of 75 patients (95% CI 8.9%-26.7%) who were allocated to or received flow diversion at any time were dead (n = 8) or dependent (n = 4) at 3 months or more, crossing a predefined safety boundary. Death or dependency occurred in 5 (13.2%) of 38 patients randomly allocated and treated by flow diversion (95% CI 5.0%-28.9%) and in 5 (12.8%) of 39 patients allocated to standard treatment (95% CI 4.8%-28.2%). Efficacy was below expectations of the trial hypothesis: 16 (42.1%) of 38 patients (95% CI 26.7%-59.1%) randomly allocated to flow diversion failed to reach the primary outcome, as compared with 14 (35.9%) of 39 patients allocated to standard treatment (95% CI 21.7%-52.9%). CONCLUSIONS Flow diversion was not as safe and effective as hypothesized. More randomized trials are needed to determine the role of flow diversion in the management of aneurysms. Clinical trial registration no.: NCT01349582 (clinicaltrials.gov).

Entities:  

Keywords:  BSO = best standard option; CI = confidence interval; DSMC = Data Safety and Monitoring Committee; FIAT = Flow Diversion in the Treatment of Intracranial Aneurysm Trial; PVO = parent vessel occlusion; aneurysm; clinical trial; flow diversion; flow diverter; mRS = modified Rankin Scale; vascular disorders

Mesh:

Year:  2016        PMID: 27813466     DOI: 10.3171/2016.4.JNS152662

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  17 in total

1.  Hydrogel versus Bare Platinum Coils in Patients with Large or Recurrent Aneurysms Prone to Recurrence after Endovascular Treatment: A Randomized Controlled Trial.

Authors:  J Raymond; R Klink; M Chagnon; S L Barnwell; A J Evans; J Mocco; B H Hoh; A S Turk; R D Turner; H Desal; D Fiorella; S Bracard; A Weill; F Guilbert; S Lanthier; A J Fox; T E Darsaut; P M White; D Roy
Journal:  AJNR Am J Neuroradiol       Date:  2017-01-12       Impact factor: 3.825

2.  Current Strategies in the Treatment of Intracranial Large and Giant Aneurysms.

Authors:  Matthias Gmeiner; Andreas Gruber
Journal:  Acta Neurochir Suppl       Date:  2021

3.  The RISE trial: A Randomized Trial on Intra-Saccular Endobridge devices.

Authors:  Jean Raymond; Anne-Christine Januel; Daniela Iancu; Daniel Roy; Alain Weill; Andrew Carlson; Tim E Darsaut
Journal:  Interv Neuroradiol       Date:  2019-11-05       Impact factor: 1.610

Review 4.  Flow diversion: what can clinicians learn from animal models?

Authors:  Robert Fahed; Tim E Darsaut; Jean-Christophe Gentric; Behzad Farzin; Igor Salazkin; Guylaine Gevry; Jean Raymond
Journal:  Neuroradiology       Date:  2017-02-27       Impact factor: 2.804

5.  Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU).

Authors:  D Atasoy; N Kandasamy; J Hart; J Lynch; S-H Yang; D Walsh; C Tolias; T C Booth
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

6.  Flow Diversion in the Treatment of Intracranial Aneurysms: A Pragmatic Randomized Care Trial.

Authors:  J Raymond; D Iancu; W Boisseau; J D B Diestro; R Klink; M Chagnon; J Zehr; B Drake; H Lesiuk; A Weill; D Roy; M W Bojanowski; C Chaalala; J L Rempel; C O'Kelly; M M Chow; S Bracard; T E Darsaut
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-04       Impact factor: 4.966

7.  Surgical or Endovascular Treatment of MCA Aneurysms: An Agreement Study.

Authors:  W Boisseau; T E Darsaut; R Fahed; J M Findlay; R Bourcier; G Charbonnier; S Smajda; J Ognard; D Roy; F Gariel; A P Carlson; E Shotar; G Ciccio; G Marnat; P B Sporns; T Gaberel; V Jecko; A Weill; A Biondi; G Boulouis; A L Bras; S Aldea; T Passeri; S Boissonneau; N Bougaci; J C Gentric; J D B Diestro; A T Omar; H M Al-Jehani; G El Hage; D Volders; Z Kaderali; I Tsogkas; E Magro; Q Holay; J Zehr; D Iancu; J Raymond
Journal:  AJNR Am J Neuroradiol       Date:  2022-09-22       Impact factor: 4.966

8.  European Stroke Organisation (ESO) guidelines on management of unruptured intracranial aneurysms.

Authors:  Nima Etminan; Diana Aguiar de Sousa; Cindy Tiseo; Romain Bourcier; Hubert Desal; Anttii Lindgren; Timo Koivisto; David Netuka; Simone Peschillo; Sabrina Lémeret; Avtar Lal; Mervyn DI Vergouwen; Gabriel Je Rinkel
Journal:  Eur Stroke J       Date:  2022-06-03

9.  Dual Testing to Achieve Low On-treatment Platelet Reactivity for Aneurysm Embolization.

Authors:  Halitcan Batur; Mehmet A Topcuoglu; Sinan Balci; Ethem M Arsava; Anil Arat
Journal:  Clin Neuroradiol       Date:  2021-04-12       Impact factor: 3.649

10.  Endosaccular Treatment of Very Large and Giant Intracranial Aneurysms with Parent Artery Preservation : Single Center Experience with Long Term Follow-up.

Authors:  Chae Wook Huh; Jae Il Lee; Chang Hwa Choi; Tae Hong Lee; Jae Young Choi; Jun Kyeung Ko
Journal:  J Korean Neurosurg Soc       Date:  2018-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.